Abstract
Our understanding of the environmental and genetic factors contributing to the wide spectrum of neuropsychiatric disorders has significantly increased in recent years. Impairment of neuronal network activity during early development has been suggested as a contributor to the emergence of neuropsychiatric pathologies later in life. Still, the neurobiological substrates underlying these disorders remain yet to be fully understood and the lack of biomarkers for early diagnosis has impeded research into curative treatment options. Here, we briefly review current knowledge on potential biomarkers for emerging neuropsychiatric disease. Moreover, we summarize recent findings on aberrant activity patterns in the context of psychiatric disease, with a particular focus on their potential as early biomarkers of neuropathologies, an essential step towards pre-symptomatic diagnosis and, thus, early intervention.
Introduction
Neurodevelopmental disorders (NDDs) are highly prevalent diseases that affect about 3% of the population worldwide. They include disorders such as schizophrenia (SCZ), some forms of epilepsy, autism spectrum disorder (ASD), and attention deficit-hyperactivity disorder (ADHD). NDDs are characterized by a wide range of symptoms, including impairments in cognition, language, emotional processing, and motor functions (Thapar et al., 2017; Savatt and Myers, 2021). Despite the devastating individual and societal burden of NDDs, no disease-modifying treatments are available, as current treatments are solely aimed to mitigate symptoms. While symptomatic treatments can alleviate some of the burdens for affected individuals, currently available treatments are only effective for some patients, only target some of the described symptoms of NDDs, and tend to have strong side-effects (Genovese and Butler, 2020; Goff, 2021).
The etiology of NDDs is multifaceted, including risk factors from genetic, epigenetic, as well as environmental sources, such as maternal immune activation during embryonal development or stress later in life (van Os and Kapur, 2009; Schmitt et al., 2014; Willsey and State, 2015; Han et al., 2021; Reichard and Zimmer-Bensch, 2021). However, despite the discovery of many new risk factors over the years, no comprehensive model of the pathophysiological mechanisms underlying NDDs has been described.
In recent years, there has been a growing understanding that developmental trajectories define the physiological and pathophysiological development of neuronal circuits (Marín, 2016). Thus, the notion of early therapeutic intervention during sensitive phases of development has gained traction in the context of potentially rescuing pathophysiological trajectories of development towards a healthy state (Veenstra-VanderWeele and Warren, 2015; Dehorter and Del Pino, 2020). However, early diagnosis of at-risk individuals before the onset of symptoms remains challenging, not only due to heterogeneity of NDDs but also due to their high levels of comorbidity, e.g., for some forms of epilepsy co-occurring with intellectual disability or ADHD co-occurring with ASD (Thapar et al., 2017). Thus, the identification of biomarkers for NDDs is essential in order to facilitate early diagnosis and, consequently, research into potential avenues of treatment.
Recent studies identified neuronal activity patterns as a potential parameter for the pre-symptomatic diagnosis of NDDs. Activity patterns were shown to be altered in patients of NDDs in a frequency-specific manner (Newson and Thiagarajan, 2019). Promisingly, in animal models of NDDs similar aberrations have been reported not only in adult animals but also during early development (Sigurdsson et al., 2010; Richter et al., 2019; Chini et al., 2020). This review focuses on early biomarkers of neuropsychiatric disease. We provide a brief overview of different neurodevelopmental psychopathologies, with a focus on two of the most prevalent NDDs, schizophrenia (SCZ) and autism spectrum disorders (ASD). Moreover, we include a summary of the current knowledge on potential biomarkers for emerging neuropsychiatric disease, before giving a brief overview of normal and aberrant activity in developing neuronal networks. A particular focus will be on relating observations from human studies to recent insights gained from animal models. Finally, we identify open questions and future research directions for linking early dysfunction of neuronal circuits with emerging disease.
Schizophrenia
SCZ is a severe neuropsychiatric disorder with onset during young adulthood. SCZ is characterized by chronic, debilitating symptoms, which have been classified as “positive” (e.g., hallucinations, delusions), “disorganized” (e.g., formal thought disorder), and “negative” (e.g., social withdrawal, anhedonia), as well as by cognitive deficits (Jauhar et al., 2022). Despite decades of research, the pathophysiological mechanisms underlying SCZ are not entirely understood. The etiology of SCZ is heterogeneous, including environmental, epigenetic, as well as genetic risk factors, the latter ranging from chromosomal aberrations to single point mutations (van Os and Kapur, 2009). A known major risk factor for SCZ is the 22q11.2 microdeletion, which, on top of cognitive impairments, often includes metabolic burdens for affected individuals (McDonald-McGinn et al., 2015). Another risk factor for NDDs, including SCZ, is disruption of DISC1 (disrupted-in-schizophrenia 1) which is involved in coordinating neuronal development (Millar et al., 2001). Additionally, environmental insults, such as maternal immune activation during pregnancy, hypoxia, and stress (Schmitt et al., 2014), alone or in combination with genetic abnormalities, are thought to contribute to the emergence of SCZ symptoms.
Treatment options for SCZ are limited to symptomatic treatment, despite the fact that many patients respond poorly to available treatments (Goff, 2021). Additionally, most therapeutic strategies solely target “positive” symptoms of schizophrenia, whereas “negative” symptoms are unaffected (Owen et al., 2016). Crucially, pre-symptomatic diagnosis of SCZ remains challenging, due to its heterogeneous etiology and the late emergence of diverse symptoms (Jauhar et al., 2022). Notably, the first symptomatic onset of SCZ tends to be preceded by a prodromal period of up to 5 years with subtle alterations in behavior and cognition, described as “basic symptoms” (e.g., thought processing and attention) and “ultra-high-risk” symptoms (e.g., brief limited intermittent psychotic episode; Klosterkötter et al., 2001; Fusar-Poli et al., 2013). Accordingly, recent studies have focused on the prodromal period, aiming to identify reliable markers of emerging psychosis (Bernardini et al., 2017; Mikanmaa et al., 2019).
Autism Spectrum Disorder
ASD comprises a heterogeneous group of NDDs, which are characterized by symptoms of impaired social interaction, restricted interests, and repetitive behaviors (Lord et al., 2020). The onset of ASD occurs at an early age, usually prior to the age of 3 years, and it has a prevalence of more than 1% of the total population. Similar to SCZ, the etiology of ASD is heterogeneous and risk factors include genetic aberrations as well as environmental or epigenetic factors (Lord et al., 2020; Savatt and Myers, 2021). ASD can be further split into syndromic (i.e., with additional symptoms associated with other neurological disorders) and non-syndromic (i.e., without additional symptoms) ASD, based on the underlying genetic aberrations. These aberrations range from heritable point mutations or chromosomal aberrations, all the way to de novo gene mutations, with the most common aberrations being mutations in synaptic genes, such as neuroligins and neurexins, or chromosomal aberrations, such as 15q11 duplications (Pinto et al., 2010; Iossifov et al., 2012; Singh and Eroglu, 2013). However, while a multitude of risk factors has been identified, no consistent model of the pathways underlying ASD has been described.
Symptomatic treatments for ASD are available, but they are often complicated by comorbidities with other disorders and only provide partial relief from symptoms (Genovese and Butler, 2020). Accordingly, a better understanding of the pathophysiological mechanisms underlying NDDs is essential in order to facilitate research into potential options for intervention.
Animal Models of Neuropsychiatric Disease
Animal models are instrumental for basic and pre-clinical research of any human condition. Over the past century, animal models have provided essential insights into the manifold pathways underlying not only animal but also human physiology (Robinson et al., 2019). Non-human primates are particularly well-suited for research on neuropsychiatric disorders. They not only exhibit complex cognitive, social, and behavioral processes, but they also offer general similarity of brain structures compared to humans, such as the expanded prefrontal cortex (PFC), which is essential for higher-order processes (Chini and Hanganu-Opatz, 2021). With the discovery of new-generation gene editing tools, non-human primate models of NDDs have received increased interest in recent years (Lin et al., 2022). Insights into the pathophysiology of ASD have been obtained based on macaque NDD models, including a reduced expression of excitatory synaptic proteins, such as glutamate receptors and PSD95, in SHANK3-deficient macaques and an increased presence of GFAP-positive astrocytes in a brain region-specific manner (Liu et al., 2016; Zhao et al., 2017; Zhou et al., 2019). However, as of yet, the limited availability of models inadequately mirrors the multifaceted spectrum of human neuropsychiatric pathologies.
The most widely used animal models in research are rodents. Despite the evolutionary split of rats and mice from humans more than 70 million years ago, they still offer similarities in brain structure and molecular pathways of neurophysiological processes, as well as many shared developmental milestones (Figure 1). While rodent models rarely replicate the full symptomatic spectrum of any human disease, they can still mirror key features of NDDs, and targeted genetic manipulation has been used to address the contribution of individual risk factors to the pathophysiological mechanisms underlying NDDs (Diamantopoulou and Gogos, 2019).
Figure 1
Developmental milestones for humans and mice. Developmental milestones are shown for human and murine development. Gestational durations are indicated on the left. Anatomical milestones (eye opening, development of hearing, expression of olfactory receptors) are indicated for each time line individually. Shared developmental processes (discontinuous activity, γ-activity, myelination) are indicated as age-matched ranges for both species. Insets depict examples of delta-brushes in humans [modified from Milh et al. (2007)] and spindle bursts in mice [modified from Shen and Colonnese (2016)] during early discontinuous activity, as well as filtered γ-oscillation in humans [modified from Synigal et al. (2020)] and in mice [modified from Bott et al. (2016)].
Biomarkers of Neuropsychiatric Disease
Biomarkers allow for clear, standardized diagnosis and monitoring of pathologies and they are crucial for research on the etiology, manifestation, and potential treatment of human disease. So far, most studies on biomarkers of neuropsychiatric disorders have focused on morphological or molecular parameters (Table 1).
Table 1
| Schizophrenia | Autism spectrum disorder | ||||
|---|---|---|---|---|---|
| Serological markers (complement components) | C1q | ↑ | Arakelyan et al. (2011) | ↑ | Corbett et al. (2007) |
| C3 | ↑ | Boyajyan et al. (2010) | ↑ | Shen et al. (2018) | |
| = | Arakelyan et al. (2011) | ||||
| ↓ | Li et al. (2016) | ||||
| C4B | ↑ | Maes et al. (1997) | ↓ | Warren et al. (1994) | |
| = | Schroers et al. (1997) | ||||
| C5 | ↑ | Ishii et al. (2018) | ↑ | Shen et al. (2018) | |
| Functional markers | EEG | Hypofrontality at rest (Knyazeva et al., 2008); hyperfrontality during task performance (Shafritz et al., 2019) | Hypofrontality at young ages (Levin et al., 2017); hyperfrontality at later ages (Stroganova et al., 2007) | ||
| fMRI | PFC hyperconnectivity during early stages (Anticevic et al., 2015) | PFC hyperconnectivity at young ages and hypoconnectivity at older ages (Jassim et al., 2021) | |||
| Anatomical markers | Volume | Reduction overall and particularly in Cg (Pantelis et al., 2003) | Increase at early stages in Th and CC, reduction at later stages (Lange et al., 2015) | ||
| Other | Prodromal phase of up to 5 years: behavioral and cognitive impairments (Klosterkötter et al., 2001) | ||||
Biomarkers of neuropsychiatric disorders.
Previously identified candidates for potential biomarkers of neurodevelopmental disorders are listed. Arrows indicate an increase or reduction of serological markers, [=] indicates no detected change. PFC, prefrontal cortex; Cg, cingulate cortex; Th, thalamus; CC, corpus callosum; EEG, electroencephalogram; fMRI, functional magnetic resonance imaging.
One group of proposed NDD biomarkers are components of the microglial signaling cascade. Microglia function as the brain’s immune system and they are essential for synaptic refinement, monitoring, pruning, and maintaining synapses throughout development (Magdalon et al., 2020). Altered expression of components of the complement cascade, which underlies microglia signaling, has been reported in patients of SCZ and ASD (Warren et al., 1994; Maes et al., 1997; Schroers et al., 1997; Corbett et al., 2007; Boyajyan et al., 2010; Arakelyan et al., 2011; Li et al., 2016; Ishii et al., 2018; Shen et al., 2018; Rey et al., 2020), yet the roles of individual complement factors in the context of specific pathophysiological changes still need to be resolved (Magdalon et al., 2020; Woo et al., 2020). Interestingly, Sager et al. (2021) highlighted the relevance of age for these interactions with a change in expression of complement factors during development and a peak during early childhood between ages 3 and 5. In addition to possible molecular parameters, anatomical factors, such as volumetric assessment of gray matter, have been proposed as biomarkers of disease (Table 1). Changes in the volume of several brain regions have been reported in patients of NDDs, the most prominent change being a reduction of brain volume at later stages of these diseases (Pantelis et al., 2003; Lange et al., 2015; Hoogman et al., 2017). Additionally, fMRI data documented altered functional connectivity within networks prior to the onset of the disease, especially hyperconnectivity at early stages of SCZ as well as ASD (Anticevic et al., 2015; Jassim et al., 2021).
On the functional level, excitation/inhibition (E/I) imbalance has been proposed as a potential biomarker. E/I balance is essential for maintaining physiological network activity and disruptions of the pathways underlying excitation and/or inhibition have been described for patients with SCZ or ASD (Gao and Penzes, 2015; Sohal and Rubenstein, 2019). It is, therefore, tempting to postulate that neuronal activity patterns could provide a potential llink between genetic aberrations, physiological changes, and impaired cognitive or behavioral functions.
Patterns of Neuronal Oscillations in Health and Disease
Precisely coordinated interactions of neurons in local and distant networks are the physiological substrate of cognitive and sensory processing, which is imperative for day-to-day survival. These network oscillations are essential for gating of incoming information (Singer, 2018) and they are conserved across species (Buzsáki et al., 2013).
Since the first electroencephalographic recordings (Berger, 1929), network oscillations within distinct frequency bands have been related to specific functions. High-frequency oscillations (gamma band, 30–100 Hz) allow for synchronization of local activity and are essential for cognitive processing, whereas slower oscillations (delta band 1–4 Hz, theta band 4–12 Hz) are more suited for coordination of distant networks, as they require less temporal precision due to the lengthened periods between alternating phases (Uhlhaas and Singer, 2013). Additionally, cross-frequency coupling between networks can mediate long-range coordination, with the phase of low-frequency oscillations in one network modulating the amplitude of high-frequency oscillations in another (Buzsáki and Draguhn, 2004).
Neuronal oscillations are known to play an essential role in cognitive processing and a link to cognitive deficits in NDDs has been postulated (Simon and Wallace, 2016; Hirano and Uhlhaas, 2021). Electroencephalographic (EEG) studies in SCZ patients have shown a general increase of power across lower-frequencies accompanied by a power decrease in the high frequency band (Newson and Thiagarajan, 2019). However, these observations depend on multiple factors, such as the task performed by the examined individuals, the stage of the disease, as well as medication. Additionally, the question of prefrontal hypo- and/or hyperactivity in NDD patients remains (Weinberger et al., 1986; Schneider et al., 2007; Stroganova et al., 2007; Knyazeva et al., 2008; Levin et al., 2017; Shafritz et al., 2019). Abnormal neuronal activity in the PFC of SCZ and ASD patients is of particular interest, as the PFC is a critical hub of cognitive functions across mammalian species (Miller, 2000). The PFC is involved in executive processes, such as attention, working memory, and decision-making, as well as social behaviors (Chini and Hanganu-Opatz, 2021), and impairments of these processes constitute the core of cognitive symptoms observed in NDDs (O’Grada and Dinan, 2007). Accordingly, many studies have focused on prefrontal function in disease and both hyper- as well as hypofrontality have been observed in SCZ and ASD patients, depending on brain state or performed task (Dawson et al., 1995; Knyazeva et al., 2008; van Diessen et al., 2015; Shafritz et al., 2019). Notably, altered prefrontal activity and connectivity have been shown in mouse models of SCZ and ASD (Fénelon et al., 2013; Crabtree et al., 2017; Wang et al., 2018). In addition, multiple studies on mouse models have identified prefrontal layer 2/3 pyramidal neurons to be particularly vulnerable to disruptions and to show structural and functional impairment, such as reduced synaptic density, in models of NDDs (Cooper and Koleske, 2014; Lazaro et al., 2019; Comer et al., 2020; Nagahama et al., 2020). Interestingly, similar alterations in spine densities have been reported in postmortem brain tissue from SCZ patients (Konopaske et al., 2014).
In SCZ and ASD patients, weaker prefrontal-hippocampal communication has been suggested to potentially underlie cognitive deficits (Meyer-Lindenberg et al., 2005; Cooper et al., 2017). Correspondingly, in mouse models of SCZ and ASD, prefrontal-hippocampal interactions are disrupted. For example, in a mouse model mirroring the human 22q11.2 microdeletion, hippocampal-prefrontal theta-frequency synchrony is decreased during working memory tasks (Sigurdsson et al., 2010). In a mouse model of ASD, manipulation of Pogz expression similarly affected prefrontal-hippocampal synchronization (Cunniff et al., 2020).
These consistent changes within prefrontal-hippocampal circuits across species, models, and pathologies, indicate that altered patterns of oscillatory activity and synchrony-based coupling might contribute to the emergence of cognitive deficits. Therefore, a key question to be addressed is whether aberrant activity patterns develops earlier, potentially even before symptomatic onset of the disease.
Early Patterns of Neuronal Activity in Schizophrenia and Autism Spectrum Disorders
Precisely timed coordination of molecular and cellular processes is required in order to define developmental trajectories early in life and all the way to adulthood. In the human CNS, the ability to respond to new experiences persists throughout development, including neuronal cell migration at embryonal ages as well as neuronal differentiation, synaptogenesis, synaptic plasticity, and synaptic pruning all the way to adulthood. However, this lasting plasticity might also imply an increased vulnerability towards insults. It has been hypothesized that the trajectory of physiological development is particularly sensitive during specific phases (Larsen and Luna, 2018; Sakurai and Gamo, 2019).
Patterns of electrical activity and their temporal coordination change alongside development (Chini and Hanganu-Opatz, 2021). Spontaneous, highly synchronized activity is a hallmark of neuronal circuits during early development (Babola et al., 2018; Martini et al., 2021). This activity is discontinuous (i.e., periods of oscillatory discharges alternate with silent periods) and has been shown for all mammalian species investigated at a comparable stage of brain development (i.e., 2nd–3rd gestational trimester in humans and early postnatal in rodents; Figure 1; Khazipov et al., 2004; Hanganu et al., 2006; Colonnese et al., 2010). Subsequent desynchronization of activity mirrors the increasing influence of sensory inputs shaping neuronal activity (Toyoizumi et al., 2013). Notably, due to different types of processed information and timelines of circuit assembly, different areas and functions exhibit distinct sensitive periods of maturation, e.g., the human visual system being particularly sensitive during the first few years of life, while language acquisition is sensitive during the first year after birth (Wiesel, 1982; Daw, 1998; Anderson and Reidy, 2012; Friedmann and Rusou, 2015; Gire et al., 2022). Similarly, in rodents, experience shapes synaptic circuits of visual and auditory systems during periods of enhanced plasticity, following eye/ear opening (Lehmann and Löwel, 2008; Rinaldi Barkat et al., 2011). Even for circuits involved in cognitive processing in mice, recent data suggested the presence of time windows exhibiting increased sensitivity.
Several studies have hypothesized that therapeutic interventions at earlier stages of development might hold promise for NDD treatment. Birth cohort studies showed developmental anomalies of behavior and cognition already in 4-year-old children, who developed SCZ later in life (Welham et al., 2009). Notably, in prodromal SCZ patients, the elevation of frontal oscillatory activity in delta and theta frequency bands has been detected (van Tricht et al., 2014), although the underlying neuronal mechanisms remain poorly understood. A comprehensive summary of available data on alterations of neuronal dynamics in SCZ patients and high-risk prodromal individuals has previously been done (Mikanmaa et al., 2019).
Similarly, mouse models of NDDs have been investigated during early development. For example, immune-challenged mice with altered DISC1 expression showed disrupted patterns of network activity in beta-gamma range in the PFC during the first two postnatal weeks (Chini et al., 2020). Additionally, prefrontal-hippocampal coupling was decreased in theta frequency bands at early ages (Xu et al., 2019; Song et al., 2022). These early deficits in neuronal activity have been proposed to contribute to poor cognitive performance at adult age. Notably, prominent dysfunctions induced by transient disruption of DISC1 expression in immune-challenged mice, as well as perinatal disruption of Arc/Arg3.1 (activity-regulated cytoskeleton-associated protein) suggest the existence of specific phases during which hippocampal and prefrontal activity play a crucial role (Gao et al., 2018, 2019; Xu et al., 2019).
In summary, these findings suggest that disruption of early neuronal activity patterns relates to the emergence of NDDs later in life and might offer a promising avenue for potential treatments.
Future Perspectives for Diagnosis and Intervention
Despite the ethical and technical challenges inherent to investigations of early human development, the data reviewed here highlight early development as a crucial time window for addressing the circuit miswiring which underlies adult cognitive burdens of neuropsychiatric disorders. Therefore, sustained efforts are necessary in order to develop tailored interventions which minimize this burden for affected individuals. Early intensive behavioral intervention (EIBI) in children with emerging ASD has shown promising results for improving adaptive behaviors later in life (Tiura et al., 2017; Reichow et al., 2018). Similarly, early intervention using psychosocial and psychopharmacological treatments immediately after the onset of psychosis has shown some promising results in SCZ patients, e.g., reduced severity of positive as well as negative symptoms (Correll et al., 2018). However, the effects of this described early intervention do not persist over time (Chan et al., 2019).
In this context, the need for reliable biomarkers of early dysfunction is evident. The wide spectrum of dynamic features inherent to neuronal oscillations might constitute a powerful tool for identifying, describing, and potentially even rerouting disorder-specific deficits. Specifically for SCZ, previous hypotheses have focused on altered neuronal activity during the prodromal period or during the time of the first episode of psychosis as a potential time window for intervention (Millan et al., 2016; Mikanmaa et al., 2019). However, the idea of sensitive phases during early development as potential points for intervention has gained traction in recent years (Dehorter and Del Pino, 2020). Particularly the roles of GABAergic signaling as well as of fast-spiking parvalbumin (PV) interneurons have been highlighted as critical modulators of sensitive periods during development (Marín, 2016). Notably, more than a decade ago, PV interneuron dysfunction was linked to the characteristic cognitive deficits of SCZ (Lewis et al., 2012).
Additionally, identifying developmental phases of aberrant activity in NDDs is a prerequisite for the rescue of physiological trajectories during development. Recently, manipulation of activity in a specific subset of prefrontal pyramidal neurons in young mice was shown to alter developmental trajectories and to have long-term effects on brain function and cognitive processes (Bitzenhofer et al., 2021). Thus, identifying aberrant patterns of early network oscillations might not only provide an approach for pre-symptomatic diagnosis but also facilitate a better understanding of NDDs. In humans, approaches for direct modulation of neuronal oscillations (e.g., transcranial alternating current stimulation) have been used in a frequency-specific manner (Fröhlich et al., 2015; Jones et al., 2020), revealing promising tools for the treatment of psychiatric disorders (Allenby et al., 2018; Ahn et al., 2019).
In conclusion, monitoring early neuronal oscillations is highly instrumental for understanding physiological and pathophysiological development. Early aberrations of neuronal activity patterns could serve as biomarkers of NDDs and thereby open up new avenues for non-invasive, pre-symptomatic diagnosis of at-risk patients, as well as provide potential tools for the directed treatment of emerging neuropsychiatric disease.
Statements
Author contributions
AG and IH-O drafted, wrote, and edited the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This work was funded by grants from the European Research Council (ERC-2015-CoG 681577 to IH-O) and the German Research Foundation (Deutsche Forschungsgemeinschaft; 437610067, 178316478, and 302153259 to IH-O).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AhnS.MellinJ. M.AlagapanS.AlexanderM. L.GilmoreJ. H.JarskogL. F.et al. (2019). Targeting reduced neural oscillations in patients with schizophrenia by transcranial alternating current stimulation. Neuroimage186, 126–136. 10.1016/j.neuroimage.2018.10.056
2
AllenbyC.FalconeM.BernardoL.WileytoP.RostainA.RamsayJ. R.et al. (2018). Transcranial direct current brain stimulation decreases impulsivity in ADHD. Brain Stimul.11, 974–981. 10.1016/j.brs.2018.04.016
3
AndersonP. J.ReidyN. (2012). Assessing executive function in preschoolers. Neuropsychol. Rev.22, 345–360. 10.1007/s11065-012-9220-3
4
AnticevicA.HuX.XiaoY.HuJ.LiF.BiF.et al. (2015). Early-course unmedicated schizophrenia patients exhibit elevated prefrontal connectivity associated with longitudinal change. J. Neurosci.35, 267–286. 10.1523/JNEUROSCI.2310-14.2015
5
ArakelyanA.ZakharyanR.KhoyetsyanA.PoghosyanD.AroutiounianR.MrazekF.et al. (2011). Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia. BMC Clin. Pathol.11:10. 10.1186/1472-6890-11-10
6
BabolaT. A.LiS.GribizisA.LeeB. J.IssaJ. B.WangH. C.et al. (2018). Homeostatic control of spontaneous activity in the developing auditory system. Neuron99, 511–524.e5. 10.1016/j.neuron.2018.07.004
7
BergerH. (1929). Über das Elektrenkephalogramm des Menschen. Arch. F. Psychiatr. Nervenkrankh.87, 527–570. 10.1007/BF01797193
8
BernardiniF.AttademoL.ClearyS. D.LutherC.ShimR. S.QuartesanR.et al. (2017). Risk prediction models in psychiatry: toward a new frontier for the prevention of mental illnesses. J. Clin. Psychiatry78, 572–583. 10.4088/JCP.15r10003
9
BitzenhoferS. H.PöpplauJ. A.ChiniM.MarquardtA.Hanganu-OpatzI. L. (2021). A transient developmental increase in prefrontal activity alters network maturation and causes cognitive dysfunction in adult mice. Neuron109, 1350–1364.e6. 10.1016/j.neuron.2021.02.011
10
BottJ.-B.MullerM.-A.JacksonJ.AubertJ.CasselJ.-C.MathisC.et al. (2016). Spatial reference memory is associated with modulation of theta-gamma coupling in the dentate gyrus. Cereb. Cortex26, 3744–3753. 10.1093/cercor/bhv177
11
BoyajyanA.KhoyetsyanA.ChavushyanA. (2010). Alternative complement pathway in schizophrenia. Neurochem. Res.35, 894–898. 10.1007/s11064-010-0126-2
12
BuzsákiG.DraguhnA. (2004). Neuronal oscillations in cortical networks. Science304, 1926–1929. 10.1126/science.1099745
13
BuzsákiG.LogothetisN.SingerW. (2013). Scaling brain size, keeping timing: evolutionary preservation of brain rhythms. Neuron80, 751–764. 10.1016/j.neuron.2013.10.002
14
ChanS. K. W.ChanH. Y. V.DevlinJ.BastiampillaiT.MohanT.HuiC. L. M.et al. (2019). A systematic review of long-term outcomes of patients with psychosis who received early intervention services. Int. Rev. Psychiatry31, 425–440. 10.1080/09540261.2019.1643704
15
ChiniM.Hanganu-OpatzI. L. (2021). Prefrontal cortex development in health and disease: lessons from rodents and humans. Trends Neurosci.44, 227–240. 10.1016/j.tins.2020.10.017
16
ChiniM.PöpplauJ. A.LindemannC.Carol-PerdiguerL.HnidaM.OberländerV.et al. (2020). Resolving and rescuing developmental miswiring in a mouse model of cognitive impairment. Neuron105, 60–74.e7. 10.1016/j.neuron.2019.09.042
17
ColonneseM. T.KaminskaA.MinlebaevM.MilhM.BloemB.LescureS.et al. (2010). A conserved switch in sensory processing prepares developing neocortex for vision. Neuron67, 480–498. 10.1016/j.neuron.2010.07.015
18
ComerA. L.JinadasaT.SriramB.PhadkeR. A.KretsgeL. N.NguyenT. P. H.et al. (2020). Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. PLoS Biol.18:e3000604. 10.1371/journal.pbio.3000604
19
CooperM. A.KoleskeA. J. (2014). Ablation of ErbB4 from excitatory neurons leads to reduced dendritic spine density in mouse prefrontal cortex. J. Comp. Neurol.522, 3351–3362. 10.1002/cne.23615
20
CooperR. A.RichterF. R.BaysP. M.Plaisted-GrantK. C.Baron-CohenS.SimonsJ. S. (2017). Reduced hippocampal functional connectivity during episodic memory retrieval in autism. Cereb. Cortex27, 888–902. 10.1093/cercor/bhw417
21
CorbettB. A.KantorA. B.SchulmanH.WalkerW. L.LitL.AshwoodP.et al. (2007). A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol. Psychiatry12, 292–306. 10.1038/sj.mp.4001943
22
CorrellC. U.GallingB.PawarA.KrivkoA.BonettoC.RuggeriM.et al. (2018). Comparison of early intervention services vs treatment as usual for early-phase psychosis. JAMA Psychiatry75, 555–565. 10.1001/jamapsychiatry.2018.0623
23
CrabtreeG. W.SunZ.KvajoM.BroekJ. A. C.FénelonK.McKellarH.et al. (2017). Alteration of neuronal excitability and short-term synaptic plasticity in the prefrontal cortex of a mouse model of mental illness. J. Neurosci.37, 4158–4180. 10.1523/JNEUROSCI.4345-15.2017
24
CunniffM. M.Markenscoff-PapadimitriouE.OstrowskiJ.RubensteinJ. L.SohalV. S. (2020). Altered hippocampal-prefrontal communication during anxiety-related avoidance in mice deficient for the autism-associated gene Pogz. eLife9:e54835. 10.7554/eLife.54835
25
DawN. W. (1998). Critical periods and amblyopi. Arch. Ophthalmol.116, 502–505. 10.1001/archopht.116.4.502
26
DawsonG.KlingerL. G.PanagiotidesH.LewyA.CastelloeP. (1995). Subgroups of autistic children based on social behavior display distinct patterns of brain activity. J. Abnorm. Child Psychol.23, 569–583. 10.1007/BF01447662
27
DehorterN.Del PinoI. (2020). Shifting developmental trajectories during critical periods of brain formation. Front. Cell. Neurosci.14:283. 10.3389/fncel.2020.00283
28
DiamantopoulouA.GogosJ. A. (2019). Neurocognitive and perceptual processing in genetic mouse models of schizophrenia: emerging lessons. Neuroscientist25, 597–619. 10.1177/1073858418819435
29
FénelonK.XuB.LaiC. S.MukaiJ.MarkxS.StarkK. L.et al. (2013). The pattern of cortical dysfunction in a mouse model of a schizophrenia-related microdeletion. J. Neurosci.33, 14825–14839. 10.1523/JNEUROSCI.1611-13.2013
30
FriedmannN.RusouD. (2015). Critical period for first language: the crucial role of language input during the first year of life. Curr. Opin. Neurobiol.35, 27–34. 10.1016/j.conb.2015.06.003
31
FröhlichF.SellersK. K.CordleA. L. (2015). Targeting the neurophysiology of cognitive systems with transcranial alternating current stimulation (tACS). Expert Rev. Neurother.15, 145–167. 10.1586/14737175.2015.992782
32
Fusar-PoliP.BorgwardtS.BechdolfA.AddingtonJ.Riecher-RösslerA.Schultze-LutterF.et al. (2013). The psychosis high-risk state. JAMA Psychiatry70, 107–120. 10.1001/jamapsychiatry.2013.269
33
GaoX.Castro-GomezS.GrendelJ.GrafS.SüsensU.BinkleL.et al. (2018). Arc/Arg3.1 mediates a critical period for spatial learning and hippocampal networks. Proc. Natl. Acad. Sci. U S A115, 12531–12536. 10.1073/pnas.1810125115
34
GaoX.GrendelJ.MuhiaM.Castro-GomezS.SüsensU.IsbrandtD.et al. (2019). Disturbed prefrontal cortex activity in the absence of schizophrenia-like behavioral dysfunction in Arc/Arg3.1 deficient mice. J. Neurosci.39, 8149–8163. 10.1523/JNEUROSCI.0623-19.2019
35
GaoR.PenzesP. (2015). Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr. Mol. Med.15, 146–167. 10.2174/1566524015666150303003028
36
GenoveseA.ButlerM. G. (2020). Clinical assessment, genetics and treatment approaches in autism spectrum disorder (ASD). Int. J. Mol. Sci.21:4726. 10.3390/ijms21134726
37
GireC.GarbiA.ZahedM.Beltran AnzolaA.ToselloB.Datin-DorrièreV. (2022). Neurobehavioral phenotype and dysexecutive syndrome of preterm children: comorbidity or trigger? An update. Children (Basel)9:239. 10.3390/children9020239
38
GoffD. C. (2021). The pharmacologic treatment of schizophrenia—2021. JAMA325, 175–176. 10.1001/jama.2020.19048
39
HanV. X.PatelS.JonesH. F.DaleR. C. (2021). Maternal immune activation and neuroinflammation in human neurodevelopmental disorders. Nat. Rev. Neurol.17, 564–579. 10.1038/s41582-021-00530-8
40
HanganuI. L.Ben-AriY.KhazipovR. (2006). Retinal waves trigger spindle bursts in the neonatal rat visual cortex. J. Neurosci.26, 6728–6736. 10.1523/JNEUROSCI.0752-06.2006
41
HiranoY.UhlhaasP. J. (2021). Current findings and perspectives on aberrant neural oscillations in schizophrenia. Psychiatry Clin. Neurosci.75, 358–368. 10.1111/pcn.13300
42
HoogmanM.BraltenJ.HibarD. P.MennesM.ZwiersM. P.SchwerenL.et al. (2017). Subcortical brain volume differences of participants with ADHD across the lifespan: an ENIGMA collaboration. Lancet Psychiatry4, 310–319. 10.1016/S2215-0366(17)30049-4
43
IossifovI.RonemusM.LevyD.WangZ.HakkerI.RosenbaumJ.et al. (2012). De novo gene disruptions in children on the autistic spectrum. Neuron74, 285–299. 10.1016/j.neuron.2012.04.009
44
IshiiT.HattoriK.MiyakawaT.WatanabeK.HideseS.SasayamaD.et al. (2018). Increased cerebrospinal fluid complement C5 levels in major depressive disorder and schizophrenia. Biochem. Biophys. Res. Commun.497, 683–688. 10.1016/j.bbrc.2018.02.131
45
JassimN.Baron-CohenS.SucklingJ. (2021). Meta-analytic evidence of differential prefrontal and early sensory cortex activity during non-social sensory perception in autism. Neurosci. Biobehav. Rev.127, 146–157. 10.1016/j.neubiorev.2021.04.014
46
JauharS.JohnstoneM.McKennaP. J. (2022). Schizophrenia. Lancet399, 473–486. 10.1016/S0140-6736(21)01730-X
47
JonesK. T.JohnsonE. L.TauxeZ. S.RojasD. C. (2020). Modulation of auditory gamma-band responses using transcranial electrical stimulation. J. Neurophysiol.123, 2504–2514. 10.1152/jn.00003.2020
48
KhazipovR.SirotaA.LeinekugelX.HolmesG. L.Ben-AriY.BuzsákiG. (2004). Early motor activity drives spindle bursts in the developing somatosensory cortex. Nature432, 758–761. 10.1038/nature03132
49
KlosterkötterJ.HellmichM.SteinmeyerE. M.Schultze-LutterF. (2001). Diagnosing schizophrenia in the initial prodromal phase. Arch. Gen. Psychiatry58, 158–164. 10.1001/archpsyc.58.2.158
50
KnyazevaM. G.JaliliM.MeuliR.HaslerM.De FeoO.DoK. Q. (2008). Alpha rhythm and hypofrontality in schizophrenia. Acta Psychiatr. Scand.118, 188–199. 10.1111/j.1600-0447.2008.01227.x
51
KonopaskeG. T.LangeN.CoyleJ. T.BenesF. M. (2014). Prefrontal cortical dendritic spine pathology in schizophrenia and bipolar disorder. JAMA Psychiatry71, 1323–1331. 10.1001/jamapsychiatry.2014.1582
52
LangeN.TraversB. G.BiglerE. D.PriggeM. B. D.FroehlichA. L.NielsenJ. A.et al. (2015). Longitudinal volumetric brain changes in autism spectrum disorder ages 6-35 years. Autism Res.8, 82–93. 10.1002/aur.1427
53
LarsenB.LunaB. (2018). Adolescence as a neurobiological critical period for the development of higher-order cognition. Neurosci. Biobehav. Rev.94, 179–195. 10.1016/j.neubiorev.2018.09.005
54
LazaroM. T.TaxidisJ.ShumanT.BachmutskyI.IkrarT.SantosR.et al. (2019). Reduced prefrontal synaptic connectivity and disturbed oscillatory population dynamics in the CNTNAP2 model of autism. Cell Rep.27, 2567–2578.e6. 10.1016/j.celrep.2019.05.006
55
LehmannK.LöwelS. (2008). Age-dependent ocular dominance plasticity in adult mice. PLoS One3:e3120. 10.1371/journal.pone.0003120
56
LevinA. R.VarcinK. J.O’LearyH. M.Tager-FlusbergH.NelsonC. A. (2017). EEG power at 3 months in infants at high familial risk for autism. J. Neurodev. Disord.9:34. 10.1186/s11689-017-9214-9
57
LewisD. A.CurleyA. A.GlausierJ. R.VolkD. W. (2012). Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci.35, 57–67. 10.1016/j.tins.2011.10.004
58
LiH.ZhangQ.LiN.WangF.XiangH.ZhangZ.et al. (2016). Plasma levels of Th17-related cytokines and complement C3 correlated with aggressive behavior in patients with schizophrenia. Psychiatry Res.246, 700–706. 10.1016/j.psychres.2016.10.061
59
LinY.LiJ.LiC.TuZ.LiS.LiX.-J.et al. (2022). Application of CRISPR/Cas9 system in establishing large animal models. Front. Cell Dev. Biol.10:919155. 10.3389/fcell.2022.919155
60
LiuZ.LiX.ZhangJ.-T.CaiY.-J.ChengT.-L.ChengC.et al. (2016). Autism-like behaviours and germline transmission in transgenic monkeys overexpressing MeCP2. Nature530, 98–102. 10.1038/nature16533
61
LordC.BrughaT. S.CharmanT.CusackJ.DumasG.FrazierT.et al. (2020). Autism spectrum disorder. Nat. Rev. Dis. Primer6:5. 10.1038/s41572-019-0138-4
62
MaesM.DelangeJ.RanjanR.MeltzerH. Y.DesnyderR.CooremansW.et al. (1997). Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res.66, 1–11. 10.1016/s0165-1781(96)02915-0
63
MagdalonJ.MansurF.Teles e SilvaA. L.de GoesV. A.ReinerO.SertiéA. L. (2020). Complement system in brain architecture and neurodevelopmental disorders. Front. Neurosci.14:23. 10.3389/fnins.2020.00023
64
MarínO. (2016). Developmental timing and critical windows for the treatment of psychiatric disorders. Nat. Med.22, 1229–1238. 10.1038/nm.4225
65
MartiniF. J.Guillamón-VivancosT.Moreno-JuanV.ValdeolmillosM.López-BenditoG. (2021). Spontaneous activity in developing thalamic and cortical sensory networks. Neuron109, 2519–2534. 10.1016/j.neuron.2021.06.026
66
McDonald-McGinnD. M.SullivanK. E.MarinoB.PhilipN.SwillenA.VorstmanJ. A. S.et al. (2015). 22q11.2 deletion syndrome. Nat. Rev. Dis. Primer1:15071. 10.1038/nrdp.2015.71
67
Meyer-LindenbergA. S.OlsenR. K.KohnP. D.BrownT.EganM. F.WeinbergerD. R.et al. (2005). Regionally specific disturbance of dorsolateral prefrontal-hippocampal functional connectivity in schizophrenia. Arch. Gen. Psychiatry62, 379–386. 10.1001/archpsyc.62.4.379
68
MikanmaaE.Grent-’t-JongT.HuaL.RecasensM.ThuneH.UhlhaasP. J. (2019). Towards a neurodynamical understanding of the prodrome in schizophrenia. Neuroimage190, 144–153. 10.1016/j.neuroimage.2017.11.026
69
MilhM.KaminskaA.HuonC.LapillonneA.Ben-AriY.KhazipovR. (2007). Rapid cortical oscillations and early motor activity in premature human neonate. Cereb. Cortex17, 1582–1594. 10.1093/cercor/bhl069
70
MillanM. J.AndrieuxA.BartzokisG.CadenheadK.DazzanP.Fusar-PoliP.et al. (2016). Altering the course of schizophrenia: progress and perspectives. Nat. Rev. Drug Discov.15, 485–515. 10.1038/nrd.2016.28
71
MillarJ. K.ChristieS.AndersonS.LawsonD.LohD. H.-W.DevonR. S.et al. (2001). Genomic structure and localisation within a linkage hotspot of disrupted in schizophrenia 1, a gene disrupted by a translocation segregating with schizophrenia. Mol. Psychiatry6, 173–178. 10.1038/sj.mp.4000784
72
MillerE. K. (2000). The prefontral cortex and cognitive control. Nat. Rev. Neurosci.1, 59–65. 10.1038/35036228
73
NagahamaK.SakooriK.WatanabeT.KishiY.KawajiK.KoebisM.et al. (2020). Setd1a insufficiency in mice attenuates excitatory synaptic function and recapitulates schizophrenia-related behavioral abnormalities. Cell Rep.32:108126. 10.1016/j.celrep.2020.108126
74
NewsonJ. J.ThiagarajanT. C. (2019). EEG frequency bands in psychiatric disorders: a review of resting state studies. Front. Hum. Neurosci.12:521. 10.3389/fnhum.2018.00521
75
O’GradaC.DinanT. (2007). Executive function in schizophrenia: what impact do antipsychotics have?Hum. Psychopharmacol.22, 397–406. 10.1002/hup.861
76
OwenM. J.SawaA.MortensenP. B. (2016). Schizophrenia. Lancet388, 86–97. 10.1016/S0140-6736(15)01121-6
77
PantelisC.VelakoulisD.McGorryP. D.WoodS. J.SucklingJ.PhillipsL. J.et al. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet361, 281–288. 10.1016/S0140-6736(03)12323-9
78
PintoD.PagnamentaA. T.KleiL.AnneyR.MericoD.ReganR.et al. (2010). Functional impact of global rare copy number variation in autism spectrum disorders. Nature466, 368–372. 10.1038/nature09146
79
ReichardJ.Zimmer-BenschG. (2021). The epigenome in neurodevelopmental disorders. Front. Neurosci.15:776809. 10.3389/fnins.2021.776809
80
ReichowB.HumeK.BartonE. E.BoydB. A. (2018). Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst. Rev.5:CD009260. 10.1002/14651858.CD009260.pub3
81
ReyR.Suaud-ChagnyM.-F.BohecA.-L.DoreyJ.-M.d’AmatoT.TamouzaR.et al. (2020). Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia. Brain Behav. Immun.90, 216–225. 10.1016/j.bbi.2020.08.019
82
RichterM.MurtazaN.ScharrenbergR.WhiteS. H.JohannsO.WalkerS.et al. (2019). Altered TAOK2 activity causes autism-related neurodevelopmental and cognitive abnormalities through RhoA signaling. Mol. Psychiatry24, 1329–1350. 10.1038/s41380-018-0025-5
83
Rinaldi BarkatT.PolleyD. B.HenschT. K. (2011). A critical period for auditory thalamocortical connectivity. Nat. Neurosci.14, 1189–1194. 10.1038/nn.2882
84
RobinsonN. B.KriegerK.KhanF. M.HuffmanW.ChangM.NaikA.et al. (2019). The current state of animal models in research: a review. Int. J. Surg.72, 9–13. 10.1016/j.ijsu.2019.10.015
85
SagerR. E. H.WalkerA. K.MiddletonF.RobinsonK.WebsterM. J.WeickertC. S. (2021). Trajectory of change in brain complement factors from neonatal to young adult humans. J. Neurochem.157, 479–493. 10.1111/jnc.15241
86
SakuraiT.GamoN. J. (2019). Cognitive functions associated with developing prefrontal cortex during adolescence and developmental neuropsychiatric disorders. Neurobiol. Dis.131:104322. 10.1016/j.nbd.2018.11.007
87
SavattJ. M.MyersS. M. (2021). Genetic testing in neurodevelopmental disorders. Front. Pediatr.9:526779. 10.3389/fped.2021.526779
88
SchmittA.MalchowB.HasanA.FalkaiP. (2014). The impact of environmental factors in severe psychiatric disorders. Front. Neurosci.8:19. 10.3389/fnins.2014.00019
89
SchneiderF.HabelU.ReskeM.KellermannT.StöckerT.ShahN. J.et al. (2007). Neural correlates of working memory dysfunction in first-episode schizophrenia patients: an fMRI multi-center study. Schizophr. Res.89, 198–210. 10.1016/j.schres.2006.07.021
90
SchroersR.NöthenM. M.RietschelM.AlbusM.MaierW.SchwabS.et al. (1997). Investigation of complement C4B deficiency in schizophrenia. Hum. Hered.47, 279–282. 10.1159/000154424
91
ShafritzK. M.IkutaT.GreeneA.RobinsonD. G.GallegoJ.LenczT.et al. (2019). Frontal lobe functioning during a simple response conflict task in first-episode psychosis and its relationship to treatment response. Brain Imaging Behav.13, 541–553. 10.1007/s11682-018-9876-2
92
ShenJ.ColonneseM. T. (2016). Development of activity in the mouse visual cortex. J. Neurosci.36, 12259–12275. 10.1523/JNEUROSCI.1903-16.2016
93
ShenL.ZhangK.FengC.ChenY.LiS.IqbalJ.et al. (2018). iTRAQ-based proteomic analysis reveals protein profile in plasma from children with autism. Proteomics Clin. Appl.12:e1700085. 10.1002/prca.201700085
94
SigurdssonT.StarkK. L.KarayiorgouM.GogosJ. A.GordonJ. A. (2010). Impaired hippocampal-prefrontal synchrony in a genetic mouse model of schizophrenia. Nature464, 763–767. 10.1038/nature08855
95
SimonD. M.WallaceM. T. (2016). Dysfunction of sensory oscillations in autism spectrum disorder. Neurosci. Biobehav. Rev.68, 848–861. 10.1016/j.neubiorev.2016.07.016
96
SingerW. (2018). Neuronal oscillations: unavoidable and useful?Eur. J. Neurosci.48, 2389–2398. 10.1111/ejn.13796
97
SinghS. K.ErogluC. (2013). Neuroligins provide molecular links between syndromic and non-syndromic autism. Sci. Signal.6:re4. 10.1126/scisignal.2004102
98
SohalV. S.RubensteinJ. L. R. (2019). Excitation-inhibition balance as a framework for investigating mechanisms in neuropsychiatric disorders. Mol. Psychiatry24, 1248–1257. 10.1038/s41380-019-0426-0
99
SongL.XuX.PutthoffP.FleckD.SpehrM.Hanganu-OpatzI. L. (2022). Sparser and less efficient hippocampal-prefrontal projections account for developmental network dysfunction in a model of psychiatric risk mediated by gene-environment interaction. J. Neurosci.42, 601–618. 10.1523/JNEUROSCI.1203-21.2021
100
StroganovaT. A.NygrenG.TsetlinM. M.PosikeraI. N.GillbergC.ElamM.et al. (2007). Abnormal EEG lateralization in boys with autism. Clin. Neurophysiol.118, 1842–1854. 10.1016/j.clinph.2007.05.005
101
SynigalS. R.TeohE. S.LalorE. C. (2020). Including measures of high gamma power can improve the decoding of natural speech from EEG. Front. Hum. Neurosci.14:130. 10.3389/fnhum.2020.00130
102
ThaparA.CooperM.RutterM. (2017). Neurodevelopmental disorders. Lancet Psychiatry4, 339–346. 10.1016/S2215-0366(16)30376-5
103
TiuraM.KimJ.DetmersD.BaldiH. (2017). Predictors of longitudinal ABA treatment outcomes for children with autism: a growth curve analysis. Res. Dev. Disabil.70, 185–197. 10.1016/j.ridd.2017.09.008
104
ToyoizumiT.MiyamotoH.Yazaki-SugiyamaY.AtapourN.HenschT. K.MillerK. D. (2013). A theory of the transition to critical period plasticity: inhibition selectively suppresses spontaneous activity. Neuron80, 51–63. 10.1016/j.neuron.2013.07.022
105
UhlhaasP. J.SingerW. (2013). High-frequency oscillations and the neurobiology of schizophrenia. Dialogues Clin. Neurosci.15, 301–313. 10.31887/DCNS.2013.15.3/puhlhaas
106
van DiessenE.SendersJ.JansenF. E.BoersmaM.BruiningH. (2015). Increased power of resting-state gamma oscillations in autism spectrum disorder detected by routine electroencephalography. Eur. Arch. Psychiatry Clin. Neurosci.265, 537–540. 10.1007/s00406-014-0527-3
107
van OsJ.KapurS. (2009). Schizophrenia. Lancet374, 635–645. 10.1016/S0140-6736(09)60995-8
108
van TrichtM. J.RuhrmannS.ArnsM.MüllerR.BodatschM.VelthorstE.et al. (2014). Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. Schizophr. Res.153, 42–47. 10.1016/j.schres.2014.01.019
109
Veenstra-VanderWeeleJ.WarrenZ. (2015). Intervention in the context of development: pathways toward new treatments. Neuropsychopharmacology40, 225–237. 10.1038/npp.2014.232
110
WangW.ReinB.ZhangF.TanT.ZhongP.QinL.et al. (2018). Chemogenetic activation of prefrontal cortex rescues synaptic and behavioral deficits in a mouse model of 16p11.2 deletion syndrome. J. Neurosci.38, 5939–5948. 10.1523/JNEUROSCI.0149-18.2018
111
WarrenR. P.BurgerR. A.OdellD.TorresA. R.WarrenW. L. (1994). Decreased plasma concentrations of the C4B complement protein in autism. Arch. Pediatr. Adolesc. Med.148, 180–183. 10.1001/archpedi.1994.02170020066011
112
WeinbergerD. R.BermanK. F.ZecR. F. (1986). Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. regional cerebral blood flow evidence. Arch. Gen. Psychiatry43, 114–124. 10.1001/archpsyc.1986.01800020020004
113
WelhamJ.IsohanniM.JonesP.McGrathJ. (2009). The antecedents of schizophrenia: a review of birth cohort studies. Schizophr. Bull.35, 603–623. 10.1093/schbul/sbn084
114
WieselT. N. (1982). Postnatal development of the visual cortex and the influence of environment. Nature299, 583–591. 10.1038/299583a0
115
WillseyA. J.StateM. W. (2015). Autism spectrum disorders: from genes to neurobiology. Curr. Opin. Neurobiol.30, 92–99. 10.1016/j.conb.2014.10.015
116
WooJ. J.PougetJ. G.ZaiC. C.KennedyJ. L. (2020). The complement system in schizophrenia: where are we now and what’s next?Mol. Psychiatry25, 114–130. 10.1038/s41380-019-0479-0
117
XuX.ChiniM.BitzenhoferS. H.Hanganu-OpatzI. L. (2019). Transient knock-down of prefrontal DISC1 in immune-challenged mice causes abnormal long-range coupling and cognitive dysfunction throughout development. J. Neurosci.39, 1222–1235. 10.1523/JNEUROSCI.2170-18.2018
118
ZhaoH.TuZ.XuH.YanS.YanH.ZhengY.et al. (2017). Altered neurogenesis and disrupted expression of synaptic proteins in prefrontal cortex of SHANK3-deficient non-human primate. Cell Res.27, 1293–1297. 10.1038/cr.2017.95
119
ZhouY.SharmaJ.KeQ.LandmanR.YuanJ.ChenH.et al. (2019). Atypical behaviour and connectivity in SHANK3-mutant macaques. Nature570, 326–331. 10.1038/s41586-019-1278-0
Summary
Keywords
biomarkers, schizophrenia, autism, development, neuronal oscillations
Citation
Günther A and Hanganu-Opatz IL (2022) Neuronal oscillations: early biomarkers of psychiatric disease?. Front. Behav. Neurosci. 16:1038981. doi: 10.3389/fnbeh.2022.1038981
Received
07 September 2022
Accepted
09 November 2022
Published
19 December 2022
Volume
16 - 2022
Edited by
Lalit K. Srivastava, McGill University, Canada
Reviewed by
Fiona E. N. LeBeau, Newcastle University, United Kingdom; Jennifer Robinson, Boston University, United States
Updates
Copyright
© 2022 Günther and Hanganu-Opatz.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Anne Günther anne.guenther@zmnh.uni-hamburg.de
Specialty section: This article was submitted to Pathological Conditions, a section of the journal Frontiers in Behavioral Neuroscience
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.